These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25394870)

  • 1. Regulatory watch: Outcomes of EMA marketing authorization applications: does partnering have an influence?
    van den Bogert CA; Souverein PC; Putzeist M; Leufkens HG; Janssen SW; Koëter GH
    Nat Rev Drug Discov; 2014 Dec; 13(12):878. PubMed ID: 25394870
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulatory watch: FDA guidance on co-developing investigational drugs.
    Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094
    [No Abstract]   [Full Text] [Related]  

  • 3. The complexity of integrating speed and safety in drug development and approval.
    Charo RA
    JAMA Intern Med; 2013 Jul; 173(13):1165-6. PubMed ID: 23568604
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulatory watch: European regulatory experience with advanced therapy medicinal products.
    Barkholt L; Voltz-Girolt C; Raine J; Salmonson T; Schüssler-Lenz M
    Nat Rev Drug Discov; 2019 Jan; 18(1):8-9. PubMed ID: 30498203
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative regulation of drug and aircraft development: lessons for regulatory reform?
    Urquhart J
    Clin Pharmacol Ther; 1997 Dec; 62(6):583-6. PubMed ID: 9433385
    [No Abstract]   [Full Text] [Related]  

  • 6. What's next after 50 years of psychiatric drug development: an FDA perspective.
    Laughren TP
    J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing times ahead.
    Goodrick S
    Lancet Neurol; 2015 Sep; 14(9):879. PubMed ID: 26293563
    [No Abstract]   [Full Text] [Related]  

  • 8. Raising the bar for market authorisation of new drugs.
    Naci H; Cylus J; Vandoros S; Sato A; Perampaladas K
    BMJ; 2012 Aug; 345():e4261. PubMed ID: 22872693
    [No Abstract]   [Full Text] [Related]  

  • 9. 2013 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2014 Feb; 13(2):85-9. PubMed ID: 24481294
    [No Abstract]   [Full Text] [Related]  

  • 10. Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics.
    Looper YJ
    Curr Opin Drug Discov Devel; 2010 Mar; 13(2):247-56. PubMed ID: 20205058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparative Review of Marketing Authorization Decisions in Switzerland, the EU, and the USA.
    Dalla Torre Di Sanguinetto S; Heinonen E; Antonov J; Bolte C
    Ther Innov Regul Sci; 2019 Jan; 53(1):86-94. PubMed ID: 29714594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Industry reneges on postmarketing trial commitments.
    Bouchie A
    Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
    [No Abstract]   [Full Text] [Related]  

  • 13. Prepare for the long haul of drug monitoring.
    Gliklich R
    Nat Med; 2010 Aug; 16(8):848. PubMed ID: 20689542
    [No Abstract]   [Full Text] [Related]  

  • 14. GAIN Act legislation: is it enough?
    Tillotson GS
    Lancet Infect Dis; 2012 Nov; 12(11):823-4. PubMed ID: 23099071
    [No Abstract]   [Full Text] [Related]  

  • 15. Medicine. Can intellectual property save drug development?
    FitzGerald GA
    Science; 2012 Oct; 338(6106):483-4. PubMed ID: 23112323
    [No Abstract]   [Full Text] [Related]  

  • 16. Lessons from Eprex for biogeneric firms.
    Louët S
    Nat Biotechnol; 2003 Sep; 21(9):956-7. PubMed ID: 12949539
    [No Abstract]   [Full Text] [Related]  

  • 17. Typical pitfalls in applications for marketing authorization of biotechnological products in Europe.
    Schneider CK; Schäffner-Dallmann G
    Nat Rev Drug Discov; 2008 Nov; 7(11):893-9. PubMed ID: 18974748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004-2014.
    Cherla A; Mossialos E; Salcher-Konrad M; Kesselheim AS; Naci H
    Clin Pharmacol Ther; 2022 Oct; 112(4):846-852. PubMed ID: 35662000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The use of nanotechnology in medicinal products in the light of European Union law].
    Jurewicz M
    Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health, Wealth, and the 21st Century Cures Act.
    Lo AW; Philipson TJ; von Eschenbach AC
    JAMA Oncol; 2016 Jan; 2(1):17-8. PubMed ID: 26513279
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.